Marc Y Donath
Affiliation: University Hospital
- Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetesClaudia Cavelti-Weder
Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland
Diabetes Care 35:1654-62. 2012..Gevokizumab is a novel, human-engineered monoclonal anti-IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type 2 diabetes...
- IL-1β activation as a response to metabolic disturbancesMarc Y Donath
University Hospital Basel, Switzerland
Cell Metab 12:427-8. 2010..A recent report in Nature Immunology (Masters et al., 2010) identifies amyloid polypeptide as an additional enhancer of IL-1β production...
- Type 2 diabetes as an inflammatory diseaseMarc Y Donath
Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, CH 4031 Basel, Switzerland
Nat Rev Immunol 11:98-107. 2011....